Data Availability StatementAll data generated or analysed in this study are included in this published article. pelvic surgery, repeated ureteral stenting and radiation are additional risk factors. Case demonstration HMOX1 We describe the impressive case of a right ureteral stent displacement inside the rectum lumen in a patient treated with Bevacizumab for pelvic recurrence of cervical malignancy. The patient was referred to our Urology Division with urinary sepsis and bilateral hydronephrosis. Right ureteral stent substitution was planned; at cystoscopy the distal loop of the stent was not visualized inside the bladder. The presence of the distal loop of the right ureteral inside the rectum was clearly shown having a CT scan. Conclusions Since Bevacizumab is definitely increasingly used in the treatment of gynaecological neoplasms and indwelling ureteral stents are often required to treat or prevent ureteral compressions, related cases are likely to be diagnosed and this complication should be considered in the management of advanced pelvic cancers. Keywords: Ureteral stent complications, Angiogenesis inhibitors, CT scan, Urinary fistula Background The association of monoclonal antibodies causing angiogenesis inhibition, like Bevacizumab, to radio and chemotherapy is known to increase the incidence of fistulae . LY 344864 S-enantiomer In particular, the final analysis of a large randomized prospective trial on the use of Bevacizumab in ladies with advanced cancers from the cervix, showed an edge in the entire survival rate in comparison to chemotherapy by itself (16.8 vs 13.3?a few months) but additionally an increased threat of fistula development (15% vs 1%) . Of be aware, all the females with fistulae acquired previously been irradiated and their history of smoking was an connected risk element. The fistulae involved the genitourinary tract in 7% of instances and the gastrointestinal [tract] in 8%. Bevacizumab is definitely, at present, the standard treatment for several neoplasms, and particular toxicities are growing which may cause major morbidity and even mortality . Ischemia and an impaired function of nitrous oxide, prostacyclins and platelets due to VEGF inhibition are the likely causes of improved fistula formation. Additional risk factors for fistulae involving the urinary tract are displayed by earlier pelvic surgery, repeated ureteral stenting and mostly [do you imply above all/ most of all?] radiation, due to its additional toxicity on microvasculature. Moreover, the placing of ureteral stents is usually required in advanced pelvic malignancy to prevent or treat hydroureteronephrosis. Herein, we statement the case of a female patient having a analysis of cervical malignancy recurrence treated with Bevacizumab, who was referred to our Urology Unit for hydronephrosis and sepsis; the LY 344864 S-enantiomer patient experienced an indwelling right ureteral stent, whose distal loop was found dislocated in the rectal lumen at CT scan. Case demonstration A 40-year-old female was referred to our Urology Division with a analysis of urinary sepsis and bilateral hydronephrosis; radical hysterectomy, bilateral salpingectomy with ovarian preservation as well as LY 344864 S-enantiomer pelvic and para-aortic lymphadenectomy for squamous cell carcinoma of the cervix had been performed 8 years earlier. The patient received adjuvant concurrent cisplatin-based chemo radiotherapy up to a total dose of 50.4?Gy; next she underwent periodical surveillance examinations which resulted negative for long term. Twenty months earlier a CT scan revealed a right-sided pelvic recurrence involving the right ureter with concurrent hydronephrosis; treatment of the recurrence required 3 further cycles of Cisplatin, Paclitaxel and Bevacizumab, obtaining a partial response at 18F-FDG PET/CT, followed by additional cycles of Bevacizumab every 3?weeks as maintenance treatment. A right ureteral stent was placed with the retrograde cystoscopic approach at the time of recurrence diagnosis to treat the associated hydronephrosis and had already been substituted twice using the same approach without problems employing hydrophilic long-permanence stents. At time of the admission, a urinary tract infection sustained by Enterococcus was under treatment with Linezolid; abdominal sonography revealed bilateral hydronephrosis, with the presence of the curled upper extremity of the stent inside the right kidney collecting system, but the lower extremity was not detected in the bladder. Substitution of the right ureteral stent was planned to treat the sepsis. At cystoscopy the distal end of the stent was not visible inside the bladder, while a fistula orifice covered with fibrin was evident on the right side from the bladder trigone, therefore the prepared treatment was suspended. A 64-detector row multiphase CT study of the pelvis and belly was performed, displaying a cross-over span of the ureteral stent from the proper side left at the amount of the sacrum, that was even more apparent with 3D making (Fig.?1), existence of gas in the ideal pyelocalyceal system, across the side from the top coil from the stent (Fig.?2) with displacement from the distal third from the stent and its own lower loop in the rectum, and right-sided pelvic tumor recurrence (Fig.?3). A postponed scan revealed the current presence of iodinated contrast materials.